title: MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.
abstract: The purpose of our current work was to evaluate the prognostic significance of tumor cell proliferation in advanced metastatic melanomas and to investigate a possible correlation between the proliferation index and blood vessel density in metastatic tissue. Sixty patients with disseminated malignant melanoma treated with four-drug chemotherapy combined with interferon-alpha were included in this study. Proliferative activity and vascularity in metastatic tissues were examined by immunohistochemistry with anti-Ki-67 (MIB-1) and anti-CD31 antibody, respectively. A significant relationship between MIB-1 index and blood vessel number was detected (rho = 0.323, p = 0.013). In survival analysis, the overall survival and disease-free survival were significantly longer (58 and 38 vs. 38 and 17 months) for patients with low MIB-1 immunoreactivity (p = 0.012 and p = 0.023, respectively). Likewise, the low MIB-1 labeling index was associated with the prolonged survival calculated from the initiation of the chemoimmunotherapy (12 vs. 7 months, p = 0.032). In multivariate Cox's proportional hazard analysis, MIB-1 positivity was an independent prognostic factor both for overall survival and for survival after beginning of the chemoimmunotherapy (p = 0.016 and p = 0.029).
authors.affiliation: Department of Oncology, Turku University Central Hospital, Turku, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Vlaykova
authors.forename: L
authors.initials: L
authors.lastname: Talve
authors.forename: M
authors.initials: M
authors.lastname: Hahka-Kemppinen
authors.forename: M
authors.initials: M
authors.lastname: Hernberg
authors.forename: T
authors.initials: T
authors.lastname: Muhonen
authors.forename: K
authors.initials: K
authors.lastname: Franssila
authors.forename: Y
authors.initials: Y
authors.lastname: Collan
authors.forename: S
authors.initials: S
authors.lastname: Pyrhönen
mesh_terms: D000328:Adult; D000368:Aged; D034961:Antigens, Nuclear; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001324:Autoantigens / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000276:immunology*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy; D019394:Ki-67 Antigen; D008297:Male; D008545:Melanoma / Q000098:blood supply* / Q000276:immunology* / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology*; D011379:Prognosis; D016016:Proportional Hazards Models; D012878:Skin Neoplasms / Q000098:blood supply* / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D016019:Survival Analysis
chemical_list: D034961:Antigens, Nuclear; D000970:Antineoplastic Agents; D001324:Autoantigens; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009687:Nuclear Proteins